RxDoctor Payments Data

Pedro Guzman, MD

Internal Medicine · Hazleton, PANPI 1174858104

Payments from drug & device makers

$1,239in general payments, 2019–2025

Across 79 payments — averaging $15.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$316
  • Novo Nordisk$250
  • AstraZeneca$131
  • Amgen$101
  • Mannkind Corporation$84
  • GSK$78
  • plus $279 from 12 others

What the payments were for

  • Food & beverage$1,16594%
  • Education$151%
  • Gifts$595%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,239 in reported general payments places this provider in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$33,466
Medicare patients
128
Services billed
364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TradjentaLinagliptin213$169,112
JardianceEmpagliflozin109$112,263
OzempicSemaglutide101$108,046
LinzessLinaclotide102$76,638
EliquisApixaban66$62,695
JanumetSitagliptin Phos/Metformin Hcl70$57,232
Trijardy XrEmpaglifloz/Linaglip/Metformin58$49,866
JanuviaSitagliptin Phosphate56$40,834
Xigduo XrDapaglifloz Propaned/Metformin36$33,351
Janumet XrSitagliptin Phos/Metformin Hcl21$28,234
Synjardy XrEmpagliflozin/Metformin Hcl28$27,451
FarxigaDapagliflozin Propanediol27$26,193
Breo ElliptaFluticasone/Vilanterol37$20,057
GlyxambiEmpagliflozin/Linagliptin25$19,311
SynjardyEmpagliflozin/Metformin Hcl24$18,084

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimTradjenta, Jardiance, Trijardy Xr, Synjardy Xr, Glyxambi$15$396,087457 claims
MerckJanumet, Januvia, Janumet Xr$14$126,300147 claims
Novo NordiskOzempic$250$108,046101 claims
AbbVieLinzess, Creon$18$84,420113 claims
PfizerEliquis$316$62,69566 claims
AstraZenecaFarxiga, Brilinta$131$31,75138 claims
GSKBreo Ellipta$78$20,05737 claims
Johnson & JohnsonXarelto$13$5,88711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Hazleton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →